Base de dados : MEDLINE
Pesquisa : G06.099.225.984 [Categoria DeCS]
Referências encontradas : 3118 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 312 ir para página                         

  1 / 3118 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28463660
[Au] Autor:Jimi S; Miyazaki M; Takata T; Ohjimi H; Akita S; Hara S
[Ad] Endereço:1​Central Laboratory for Pathology and Morphology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
[Ti] Título:Increased drug resistance of meticillin-resistant Staphylococcus aureus biofilms formed on a mouse dermal chip model.
[So] Source:J Med Microbiol;66(4):542-550, 2017 Apr.
[Is] ISSN:1473-5644
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Meticillin-resistant Staphylococcus aureus (MRSA) biofilm formation in humans is of serious clinical concern. Previous in vitro studies have been performed with biofilms grown only on inorganic substrates; therefore, we investigated the vancomycin (VCM) resistance of MRSA biofilms grown on skin tissue. METHODOLOGY: We established a novel tissue substrate model, namely MRSA grown on segments of mouse skin tissue (dermal chips, DCs), and compared its resistance capacity against VCM with that of MRSA biofilms grown on plastic chips (PCs).Results/Key findings. For one MRSA isolate, we found that the VCM MIC was identical (1.56 µg ml-1) for planktonic cultures and for biofilms-formed on PCs (PC-BF), although the minimum bactericidal concentration (MBC) increased to 6.25 µg ml-1 in PC-BF. On the contrary, the MIC and MBC for biofilms formed on DCs (DC-BF) significantly increased (25 and 50 µg ml-1, respectively). Furthermore, the minimum biofilm-eradicating concentration was higher for DC-BF (100 µg ml-1) than for PC-BF (25 µg ml-1). Using six MRSA strains, we found that in PC-BF, the c.f.u. number decreased with increasing VCM concentration, whereas in DC-BF, it greatly increased until the MIC was reached, accompanied by the formation of large colonies, thicker bacterial walls and the presence of many mitotic cells. CONCLUSION: Our results indicate that the VCM resistance of MRSA was greater in DC-BF. We conclude that DCs may provide a specific environment for MRSA that enhances bacterial growth under cytotoxic VCM concentrations, and might be useful for the study of skin wound infections and the effects of antimicrobial drugs.
[Mh] Termos MeSH primário: Antibacterianos/farmacologia
Biofilmes/efeitos dos fármacos
Biofilmes/crescimento & desenvolvimento
Staphylococcus aureus Resistente à Meticilina/efeitos dos fármacos
Resistência a Vancomicina/fisiologia
Vancomicina/farmacologia
[Mh] Termos MeSH secundário: Animais
Feminino
Staphylococcus aureus Resistente à Meticilina/crescimento & desenvolvimento
Staphylococcus aureus Resistente à Meticilina/isolamento & purificação
Camundongos
Camundongos Endogâmicos C57BL
Testes de Sensibilidade Microbiana
Técnicas de Cultura de Órgãos
Pele/microbiologia
Infecções Estafilocócicas/tratamento farmacológico
Infecções Estafilocócicas/microbiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 6Q205EH1VU (Vancomycin)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:180221
[Lr] Data última revisão:
180221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE
[do] DOI:10.1099/jmm.0.000461


  2 / 3118 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28464539
[Au] Autor:Oravcova V; Svec P; Literak I
[Ad] Endereço:Department of Biology and Wildlife Diseases, Faculty of Veterinary Hygiene and Ecology, University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic.
[Ti] Título:Vancomycin-resistant enterococci with vanA and vanB genes in Australian gulls.
[So] Source:Environ Microbiol Rep;9(3):316-318, 2017 Jun.
[Is] ISSN:1758-2229
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:This study is revealing the possible dissemination of vancomycin-resistant enterococci (VRE) from humans into the wildlife. We studied silver gulls (Chroicocephalus novaehollandiae) in Australia as potential carriers and reservoirs of VRE with acquired vancomycin resistance. In New South Wales (Australia), we have found two multi-resistant isolates belonging to Enterococcus faecium (sequence type 341, vanB genotype) and Enterococcus dispar (vanA genotype). Based on our knowledge, this is the first report of VRE in Australian wildlife.
[Mh] Termos MeSH primário: Proteínas de Bactérias/genética
Carbono-Oxigênio Ligases/genética
Charadriiformes/microbiologia
Enterococcus faecium/genética
Resistência a Vancomicina/genética
Enterococos Resistentes à Vancomicina/genética
Enterococos Resistentes à Vancomicina/isolamento & purificação
[Mh] Termos MeSH secundário: Animais
Austrália
Vetores de Doenças
Enterococcus faecium/efeitos dos fármacos
Enterococcus faecium/isolamento & purificação
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bacterial Proteins); 0 (VanA ligase, Bacteria); EC 6.1.- (Carbon-Oxygen Ligases)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180116
[Lr] Data última revisão:
180116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE
[do] DOI:10.1111/1758-2229.12542


  3 / 3118 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29245276
[Au] Autor:Chen CH; Lin LC; Chang YJ; Chang CY
[Ad] Endereço:aCenter of Infection Prevention and ControlbDivision of Infectious Diseases, Department of Internal Medicine, Yuanlin Christian Hospital, ChanghuacDepartment of Nursing, College of Medicine & Nursing, Hung Kuang University, Sha-lu District, TaichungdEpidemiology and Biostatics Center, Changhua Christian HospitaleDepartment of Internal Medicine,Yuanlin Christian Hospital, Changhua, Taiwan.
[Ti] Título:Clinical and microbiological characteristics of vancomycin-resistant Enterococcus faecium bloodstream infection in Central Taiwan.
[So] Source:Medicine (Baltimore);96(49):e9000, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Bloodstream infections (BSIs) due to vancomycin-resistant Enterococcus faecium (VREfae) remain a therapeutic challenge. This study aimed to evaluate mortality from BSIs due to VREfae in Central Taiwan.We retrospectively analyzed patients with significant VREfae BSIs in the Changhua Christian Hospital System between January 1, 2010 and December 31, 2014.Of the 152 patients with Enterococcal BSI, 56 patients (36.8%) were admitted to intensive care units (ICUs) at the onset of BSI and 20 (13.2%) patients were associated with polymicrobial bacteremia. VREfae BSI was observed in 36 (23.7%) patients. Van A (100%) is the prevalence genotype, and ST 17 (41.7%) is the predominant ST type among 36 VREfae isolates during the study period. The 30-day mortality rate was 13.2% (20/152). The multivariate logistic regression analysis showed that the onset of VREfae BSI in the ICU (odds ratio [OR] = 4.2, 95% confidence interval [CI] = 1.7-10.0, P = .002) was a significant risk factor for 30-day mortality, whereas an appropriate antimicrobial therapy was a protective factor for 30-day mortality (OR = 0.33, 95% CI = 0.14-0.79, P = .013).Our results underscore the need to assist patients who are admitted to ICUs with VREfae BSIs. We emphasize the use of an appropriate antimicrobial therapy for VREfae BSI with the aim to treat more patients with these infections.
[Mh] Termos MeSH primário: Bacteriemia/microbiologia
Enterococcus faecium
Infecções por Bactérias Gram-Positivas/fisiopatologia
Resistência a Vancomicina
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Antibacterianos/uso terapêutico
Bacteriemia/tratamento farmacológico
Bacteriemia/epidemiologia
Técnicas Bacteriológicas
Feminino
Genótipo
Infecções por Bactérias Gram-Positivas/tratamento farmacológico
Infecções por Bactérias Gram-Positivas/epidemiologia
Seres Humanos
Masculino
Meia-Idade
Fatores de Risco
Taiwan/epidemiologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Anti-Bacterial Agents)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180105
[Lr] Data última revisão:
180105
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171217
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009000


  4 / 3118 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28880552
[Au] Autor:Ni S; Wei H; Li B; Chen F; Liu Y; Chen W; Xu Y; Qiu X; Li X; Lu Y; Liu W; Hu L; Lin D; Wang M; Zheng X; Mao F; Zhu J; Lan L; Li J
[Ad] Endereço:Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology , Shanghai 200237, China.
[Ti] Título:Novel Inhibitors of Staphyloxanthin Virulence Factor in Comparison with Linezolid and Vancomycin versus Methicillin-Resistant, Linezolid-Resistant, and Vancomycin-Intermediate Staphylococcus aureus Infections in Vivo.
[So] Source:J Med Chem;60(19):8145-8159, 2017 Oct 12.
[Is] ISSN:1520-4804
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Our previous work ( Wang et al. J. Med. Chem. 2016 , 59 , 4831 - 4848 ) revealed that effective benzocycloalkane-derived staphyloxanthin inhibitors against methicillin-resistant Staphylococcus aureus (S. aureus) infections were accompanied by poor water solubility and high hERG inhibition and dosages (preadministration). In this study, 92 chroman and coumaran derivatives as novel inhibitors have been addressed for overcoming deficiencies above. Derivatives 69 and 105 displayed excellent pigment inhibitory activities and low hERG inhibition, along with improvement of solubility by salt type selection. The broad and significantly potent antibacterial spectra of 69 and 105 were displayed first with normal administration in the livers and hearts in mice against pigmented S. aureus Newman, Mu50 (vancomycin-intermediate S. aureus), and NRS271 (linezolid-resistant S. aureus), compared with linezolid and vancomycin. In summary, both 69 and 105 have the potential to be developed as good antibacterial candidates targeting virulence factors.
[Mh] Termos MeSH primário: Antibacterianos/síntese química
Antibacterianos/farmacologia
Linezolida/farmacologia
Staphylococcus aureus Resistente à Meticilina/efeitos dos fármacos
Infecções Estafilocócicas/tratamento farmacológico
Vancomicina/farmacologia
Xantofilas/antagonistas & inibidores
[Mh] Termos MeSH secundário: Animais
Antibacterianos/farmacocinética
Antifúngicos/farmacologia
Farmacorresistência Bacteriana/efeitos dos fármacos
Canais de Potássio Éter-A-Go-Go/efeitos dos fármacos
Masculino
Camundongos
Camundongos Endogâmicos BALB C
Testes de Sensibilidade Microbiana
Bloqueadores dos Canais de Potássio/farmacologia
Ratos
Ratos Sprague-Dawley
Infecções Estafilocócicas/microbiologia
Relação Estrutura-Atividade
Resistência a Vancomicina/efeitos dos fármacos
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Antifungal Agents); 0 (Ether-A-Go-Go Potassium Channels); 0 (Potassium Channel Blockers); 0 (Xanthophylls); 6Q205EH1VU (Vancomycin); 71869-01-7 (staphyloxanthin); ISQ9I6J12J (Linezolid)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171030
[Lr] Data última revisão:
171030
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170908
[St] Status:MEDLINE
[do] DOI:10.1021/acs.jmedchem.7b00949


  5 / 3118 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28854219
[Au] Autor:Shekarabi M; Hajikhani B; Salimi Chirani A; Fazeli M; Goudarzi M
[Ad] Endereço:Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
[Ti] Título:Molecular characterization of vancomycin-resistant Staphylococcus aureus strains isolated from clinical samples: A three year study in Tehran, Iran.
[So] Source:PLoS One;12(8):e0183607, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Emergence of vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant S. aureus (VRSA) strains has led to great concern in global public health in both developing and developed countries. This study investigated distribution and molecular characterization of VRSA strains in Tehran's hospitals using a combination of molecular typing methods. MATERIALS AND METHODS: A total of 1789 S. aureus isolates obtained between 2014 and 2017 and were characterized using antibiogram, SCCmec typing, spa typing, and multilocus-sequence typing. Resistance to vancomycin was determined by E-test method. After confirmation of the isolated VRSA strain, genetic analysis was performed by evaluating vanA and vanB genes presence.The presence of resistance (ermA, ermB, ermC, mupA, msrA, msrB, tetM, ant (4΄)-Ia, aac (6΄)-Ie/aph (2˝), aph (3΄)-IIIa) and toxin (etb, eta, pvl, tst) encoding genes was investigated by the polymerase chain reaction (PCR) technique. RESULTS: Of all S. aureus tested isolates, four isolates were confirmed as VRSA isolates and two isolates confirmed as VISA isolates. ST5- SCCmec II/t002 and ST239-SCCmec III/t037 strains had MIC values of 512µg/ml, ST239-SCCmec III/t037 and ST8-SCCmecIV/t008 strains had MIC values of 64µg/ml and ST22-SCCmec IV/t790 and ST239-SCCmec III/t030 strains had MIC values ≥ 8 µg/ml. pvl-encoding gene was confirmed in ST8-SCCmecIV/t008 and ST22-SCCmec IV/t790 strains. The isolates differed in the carriage of resistance and toxin encoding genes. CONCLUSIONS: The study revealed the existence of VRSA strains in capital of Iran, Tehran. To our knowledge, this is the first report of ST239-SCCmec III/t037 as VRSA strain. These findings support the need for future surveillance studies on VRSA strains to keep the emergence and transmission of these isolates to a minimum.
[Mh] Termos MeSH primário: Infecção Hospitalar/microbiologia
Infecções Estafilocócicas/microbiologia
Staphylococcus aureus/genética
Resistência a Vancomicina/genética
[Mh] Termos MeSH secundário: Proteínas de Bactérias/genética
Toxinas Bacterianas/genética
Técnicas de Tipagem Bacteriana/métodos
Carbono-Oxigênio Ligases/genética
Infecção Hospitalar/epidemiologia
Exotoxinas/genética
Genes Bacterianos/genética
Hospitais
Seres Humanos
Irã (Geográfico)/epidemiologia
Leucocidinas/genética
Testes de Sensibilidade Microbiana/métodos
Proteínas Nucleares/genética
Proteínas de Ligação às Penicilinas/genética
Reação em Cadeia da Polimerase
Infecções Estafilocócicas/epidemiologia
Staphylococcus aureus/classificação
Staphylococcus aureus/fisiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bacterial Proteins); 0 (Bacterial Toxins); 0 (Exotoxins); 0 (Leukocidins); 0 (Nuclear Proteins); 0 (Panton-Valentine leukocidin); 0 (Penicillin-Binding Proteins); 0 (VanA ligase, Bacteria); 0 (mecA protein, Staphylococcus aureus); 0 (mupA protein, Staphylococcus aureus); EC 6.1.- (Carbon-Oxygen Ligases)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171023
[Lr] Data última revisão:
171023
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170831
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0183607


  6 / 3118 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28764660
[Au] Autor:Martirosov DM; Bidell MR; Pai MP; Scheetz MH; Rosenkranz SL; Faragon C; Malik M; Mendes RE; Jones RN; McNutt LA; Lodise TP
[Ad] Endereço:Albany College of Pharmacy and Health Sciences, Albany, NY, 12208-3492, USA.
[Ti] Título:Relationship between day 1 and day 2 Vancomycin area under the curve values and emergence of heterogeneous Vancomycin-intermediate Staphylococcus aureus (hVISA) by Etest® macromethod among patients with MRSA bloodstream infections: a pilot study.
[So] Source:BMC Infect Dis;17(1):534, 2017 Aug 02.
[Is] ISSN:1471-2334
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: In vitro data suggests that suboptimal initial vancomycin exposure may select for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) infections. However, no clinical studies have evaluated the relationship between initial vancomycin exposure and emergence of hVISA. This pilot study seeks to assess the relationship between day 1 and day 2 vancomycin area under the curve (AUC) and emergence of hVISA bloodstream infections (BSIs) by Etest® macromethod among patients with a non-hVISA BSI at baseline. METHODS: This was a retrospective cohort study of patients with methicillin-resistant Staphylococcus aureus (MRSA) BSIs at Albany Medical Center Hospital (AMCH) between January 2005 and June 2009. The vancomycin AUC exposure variables on day 1 (AUC ) and day 2 (AUC ) were estimated using the maximal a posteriori probability (MAP) procedure in ADAPT 5. RESULTS: There were 238 unique episodes of MRSA BSIs during the study period, 119 of which met inclusion criteria. Overall, hVISA emerged in 7/119 (5.9%) of patients. All 7 cases of hVISA involved patients who did not achieve area under the curve over broth microdilution minimum inhibitory concentration (AUC /MIC ) ratio of 521 or an AUC /MIC ratio of 650. No associations between other day 1 and day 2 AUC variables and emergence of hVISA were noted. CONCLUSIONS: Although more data are needed to draw definitive conclusions, these findings suggest that hVISA emergence among patients with non-hVISA MRSA BSIs at baseline may be partially explained by suboptimal exposure to vancomycin in the first 1 to 2 days of therapy. At a minimum, these findings support further study of the relationship between initial vancomycin exposure and hVISA emergence among patients with MRSA BSIs in a well-powered, multi-center, prospective trial.
[Mh] Termos MeSH primário: Antibacterianos/farmacocinética
Bacteriemia/microbiologia
Infecções Estafilocócicas/microbiologia
Staphylococcus aureus/efeitos dos fármacos
Vancomicina/farmacocinética
[Mh] Termos MeSH secundário: Antibacterianos/farmacologia
Área Sob a Curva
Bacteriemia/tratamento farmacológico
Testes de Sensibilidade a Antimicrobianos por Disco-Difusão
Seres Humanos
Staphylococcus aureus Resistente à Meticilina/efeitos dos fármacos
Staphylococcus aureus Resistente à Meticilina/patogenicidade
Projetos Piloto
Estudos Prospectivos
Estudos Retrospectivos
Infecções Estafilocócicas/tratamento farmacológico
Staphylococcus aureus/patogenicidade
Vancomicina/farmacologia
Resistência a Vancomicina/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 6Q205EH1VU (Vancomycin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171023
[Lr] Data última revisão:
171023
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170803
[St] Status:MEDLINE
[do] DOI:10.1186/s12879-017-2609-0


  7 / 3118 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28656013
[Au] Autor:McGuinness WA; Malachowa N; DeLeo FR
[Ad] Endereço:Laboratory of Bacteriology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT.
[Ti] Título:Vancomycin Resistance in 
.
[So] Source:Yale J Biol Med;90(2):269-281, 2017 Jun.
[Is] ISSN:1551-4056
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The evolution of during the modern antibiotic era has been delineated by distinct strain emergence events, many of which include acquisition of antibiotic resistance. The relative high burden of methicillin-resistant (MRSA) in healthcare and community settings is a major concern worldwide. Vancomycin, a glycopeptide antibiotic that inhibits cell wall biosynthesis, remains a drug of choice for treatment of severe MRSA infections. strains exhibiting increased resistance to vancomycin, known as vancomycin intermediate-resistant (VISA) (MIC = 4-8 µg/mL), were discovered in the 1990s. The molecular basis of resistance in VISA is polygenic and involves stepwise mutations in genes encoding molecules predominantly involved in cell envelope biosynthesis. isolates with complete resistance to vancomycin (MIC ≥ 16 µg/mL) are termed vancomycin-resistant (VRSA)-they were first reported in the U.S. in 2002. Resistance in VRSA is conferred by the gene and operon, which is present on a plasmid. Although treatment of VRSA infections is challenging, the total number of human VRSA infections to date is limited (14 in the U.S.). By comparison, the burden of VISA is relatively high and the molecular mechanisms of resistance are less well-defined. VISA are associated with persistent infections, vancomycin treatment failure, and poor clinical outcomes. Here, we review in brief progress made toward understanding the acquisition of antibiotic resistance in , with an emphasis on the molecular mechanisms underlying vancomycin resistance.
[Mh] Termos MeSH primário: Infecções Estafilocócicas/tratamento farmacológico
Staphylococcus aureus/efeitos dos fármacos
Resistência a Vancomicina
[Mh] Termos MeSH secundário: Seres Humanos
Staphylococcus aureus Resistente à Meticilina/efeitos dos fármacos
Staphylococcus aureus Resistente à Meticilina/genética
Infecções Estafilocócicas/microbiologia
Staphylococcus aureus/genética
Resistência a Vancomicina/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171011
[Lr] Data última revisão:
171011
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170629
[St] Status:MEDLINE


  8 / 3118 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28654976
[Au] Autor:Morgan DJ; Wenzel RP; Bearman G
[Ad] Endereço:Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore2VA Maryland Healthcare System, Baltimore.
[Ti] Título:Contact Precautions for Endemic MRSA and VRE: Time to Retire Legal Mandates.
[So] Source:JAMA;318(4):329-330, 2017 07 25.
[Is] ISSN:1538-3598
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Transmissão de Doença Infecciosa/prevenção & controle
Infecções por Bactérias Gram-Positivas/transmissão
Controle de Infecções/legislação & jurisprudência
Staphylococcus aureus Resistente à Meticilina
Resistência a Vancomicina
[Mh] Termos MeSH secundário: Centers for Disease Control and Prevention (U.S.)
Transmissão de Doença Infecciosa/legislação & jurisprudência
Enterococcus
Regulamentação Governamental
Infecções por Bactérias Gram-Positivas/prevenção & controle
Guias como Assunto
Seres Humanos
Controle de Infecções/métodos
Isolamento de Pacientes
Infecções Estafilocócicas/prevenção & controle
Infecções Estafilocócicas/transmissão
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170912
[Lr] Data última revisão:
170912
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170628
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2017.7419


  9 / 3118 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28651522
[Au] Autor:Mücke MM; Kessel J; Mücke VT; Schwarzkopf K; Hogardt M; Stephan C; Zeuzem S; Kempf VAJ; Lange CM
[Ad] Endereço:Department of Internal Medicine 1, University Hospital Frankfurt, Frankfurt am Main, Germany.
[Ti] Título:The role of Enterococcus spp. and multidrug-resistant bacteria causing pyogenic liver abscesses.
[So] Source:BMC Infect Dis;17(1):450, 2017 Jun 26.
[Is] ISSN:1471-2334
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Pyogenic liver abscesses (PLA) remain a significant clinical problem. Unfortunately, little is known about current bacterial susceptibility profiles and the incidence of multidrug resistant organisms (MDROs) causing PLA in Western countries. Yet, this crucial information is pivotal to guide empirical antibiotic therapy. Aim of this study was to provide detailed characteristics of PLA with a special focus on underlying bacterial pathogens and their susceptibility to antibiotics. METHODS: A retrospective study of patients diagnosed with PLA from 2009 to 2015 in a large tertiary reference center in Germany was performed in order to characterize PLA and antimicrobial susceptibility profiles of causative bacterial species. RESULTS: Overall, 86 patients were included. The most common causes of PLA were bile duct stenosis/obstruction (31.4%) and leakage of biliary anastomosis (15.1%). Frequent predisposing diseases were malignancies (34.9%), diabetes (24.4%) and the presence of liver cirrhosis (16.3%). Of note, Enterococcus spp. were the most frequently cultured bacterial isolates (28.9%), and in 1/3 of cases vancomycin resistance was observed. In addition, a relevant frequency of gram-negative MDROs was identified. In particular, an alarming 10% and 20% of gram-negative bacteria were resistant to carbapenems and tigecycline, respectively. Of note, MDRO status did not predict ICU stay or survival in multivariate regression analysis. The mortality rate in our series was 16.3%. CONCLUSION: Our study demonstrates an as yet underreported role of Enterococcus spp., often associated with vancomycin resistance, as well as of gram-negative MDROs causing PLA.
[Mh] Termos MeSH primário: Antibacterianos/uso terapêutico
Farmacorresistência Bacteriana Múltipla/efeitos dos fármacos
Enterococcus/efeitos dos fármacos
Abscesso Hepático Piogênico/microbiologia
[Mh] Termos MeSH secundário: Idoso
Carbapenêmicos/uso terapêutico
Farmacorresistência Bacteriana Múltipla/fisiologia
Enterococcus/isolamento & purificação
Feminino
Alemanha
Bactérias Gram-Negativas/isolamento & purificação
Seres Humanos
Abscesso Hepático Piogênico/etiologia
Abscesso Hepático Piogênico/terapia
Masculino
Testes de Sensibilidade Microbiana
Meia-Idade
Minociclina/análogos & derivados
Minociclina/farmacologia
Estudos Retrospectivos
Resultado do Tratamento
Resistência a Vancomicina/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Carbapenems); 70JE2N95KR (tigecycline); FYY3R43WGO (Minocycline)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171002
[Lr] Data última revisão:
171002
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170628
[St] Status:MEDLINE
[do] DOI:10.1186/s12879-017-2543-1


  10 / 3118 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28588223
[Au] Autor:Tabuchi F; Matsumoto Y; Ishii M; Tatsuno K; Okazaki M; Sato T; Moriya K; Sekimizu K
[Ad] Endereço:Laboratory of Microbiology, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.
[Ti] Título:D-cycloserine increases the effectiveness of vancomycin against vancomycin-highly resistant Staphylococcus aureus.
[So] Source:J Antibiot (Tokyo);70(8):907-910, 2017 Jul.
[Is] ISSN:0021-8820
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:Vancomycin is a widely used clinical drug to treat for infection by methicillin-resistant Staphylococcus aureus. Some patients show a weak response to vancomycin treatment. We previously reported that ß-lactams increase the susceptibility to vancomycin by vancomycin-highly resistant S. aureus (VRSA) strains obtained following repeated in vitro mutagenesis and vancomycin selection. Here we found that the susceptibility of the VRSA strains to vancomycin was remarkably increased by combined treatment with D-cycloserine. On the other hand, VRSA did not show increased susceptibility to vancomycin in combination with bacitracin, fosfomycin, erythromycin, lincomycin, gentamicin, levofloxacin or nisin. Furthermore, in an in vivo infection model with silkworms, combined treatment with vancomycin and D-cycloserine exhibited therapeutic effects, whereas treatment with each compound alone did not. These findings suggest that combined treatment with vancomycin and D-cycloserine could be therapeutically effective against infectious diseases caused by VRSA.
[Mh] Termos MeSH primário: Antibacterianos/farmacologia
Ciclosserina/farmacologia
Infecções Estafilocócicas/tratamento farmacológico
Staphylococcus aureus/efeitos dos fármacos
Vancomicina/farmacologia
[Mh] Termos MeSH secundário: Animais
Antibacterianos/administração & dosagem
Bombyx
Ciclosserina/administração & dosagem
Modelos Animais de Doenças
Sinergismo Farmacológico
Testes de Sensibilidade Microbiana
Infecções Estafilocócicas/microbiologia
Vancomicina/administração & dosagem
Resistência a Vancomicina
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 6Q205EH1VU (Vancomycin); 95IK5KI84Z (Cycloserine)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170808
[Lr] Data última revisão:
170808
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170608
[St] Status:MEDLINE
[do] DOI:10.1038/ja.2017.56



página 1 de 312 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde